Elderly cancer patients test how well they tolerate new immune treatments
NCT ID NCT03673332
Summary
This study looked at how safe immunotherapy drugs are and how they affect quality of life for patients aged 70 and older with advanced melanoma or lung cancer. Researchers monitored side effects and daily wellbeing while patients received standard immunotherapy treatments. The goal was to better understand how older adults tolerate these cancer therapies.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED OR METASTATIC NSCLC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Assistance Publique des Hôpitaux de Marseille
Marseille, Bouches Du Rhône, 13385, France
-
CENTRE Francois Baclesse
Caen, France
-
Centre Georges François Leclerc
Dijon, 21079, France
-
IUCT-Oncopole Institut Claudius Rigaud
Toulouse, France
-
Institut BERGONIE
Bordeaux, France
-
Institut Curie
Paris, France
-
Institut De Cancérologie de l'Ouest
Saint-Herblain, France
-
Institut Du Cancer de Montpellier
Montpellier, 34298, France
-
Institut Paoli-Calmettes
Marseille, Bouches-du Rhône, 13009, France
Conditions
Explore the condition pages connected to this study.